7 | | ZC4H2 | 'replicatively senescent; grown until growth arrest' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
6.7 | | ZC4H2 | 'young cells' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
-6.2 | | ZC4H2 | 'lipopolysaccharide' vs 'none' in 'systemic-onset juvenile idiopathic arthritis' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
5.5 | | ZC4H2 | 'aging cells' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
-5.4 | | ZC4H2 | 'anti-m6A' vs 'none' | treatment | Transcription profiling by high throughput sequencing in identification of m6A modified sequences in HepG2 cells |
-4.8 | | ZC4H2 | 'tongue squamous cell carcinoma' vs 'normal' in 'vehicle' | compound, disease | Transcription profiling by high throughput sequencing of retinoic acid treated human oral squamous cell carcinoma cells and normal cells |
-3.7 | | ZC4H2 | 'lipopolysaccharide' vs 'none' in 'normal' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
-3.7 | | ZC4H2 | "after autologous stem cell transplantation" vs "before autologous stem cell transplantation" | time | RNA-seq of human multiple myeloma patients myeloid-derived suppressor cells (M-MDSC) |
3.4 | | ZC4H2 | 'estrogen receptor alpha shRNA' vs 'scrambled shRNA' | RNA interference | RNA-seq of the human breast cancer ERα-suppressed MCF-7(MCF-7/SP10+) cells and of their internal control MCF-7 (MCF-7/C) cells |
3.4 | | ZC4H2 | 'Snail overexpression' vs 'control' | treatment | Expression data from breast cancer cell line MCF-7 with ectopic expression of the transcription factor Snail |
-3.4 | | ZC4H2 | 'erythroleukemia; ZRSR2 shRNA' vs 'normal' | disease, genotype | RNA-seq of bone marrow from patients with myelodysplastic syndrome |
3.1 | | ZC4H2 | 'estrogen receptor alpha knockdown' vs 'control' | phenotype | Expression data from MCF7 cell line after silencing of Estrogen receptor |
-3 | | ZC4H2 | 'SOX2 overexpression' vs 'wild type' in 'U-2982' | cell line, phenotype | RNA-seq of human glioblastoma cell lines with overexpression of SOX2, SFRP2 |
3 | | ZC4H2 | 'expression of estrogen receptor beta fused to C terminus tandem affinity purification tag' vs 'expression of estrogen receptor alpha fused to C terminus tandem affinity purification tag' | genotype | The nuclear receptor ERbeta engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading. Part 4 |
-2.9 | | ZC4H2 | 'Growth Medium' vs 'none' in 'systemic-onset juvenile idiopathic arthritis' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
2.8 | | ZC4H2 | ''none' in 'brown adiopcyte precursor' vs 'none' in 'white adiopcyte precursor' | cell type, stimulus | Isolation and Characterization of Clonal Adult Human Brown Adipocytes |
-2.7 | | ZC4H2 | 'sodium metavanadate' vs 'control' | compound | Sodium metavanadate exhibits carcinogenic tendencies in vitro in immortalized human bronchial epithelial cells [DEG.C] |
-2.5 | | ZC4H2 | 'KLF17 overexpression' at '24 day' vs 'wild type' at '0 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
2.3 | | ZC4H2 | 'none' in 'differentiated brown adiopcyte' vs 'none' in 'differentiated white adiopcyte' | cell type, stimulus | Isolation and Characterization of Clonal Adult Human Brown Adipocytes |
2.2 | | ZC4H2 | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'Klinefelter's syndrome' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
2.2 | | ZC4H2 | 'cyclic AMP' in 'differentiated brown adiopcyte' vs 'cyclic AMP' in 'differentiated white adiopcyte' | cell type, stimulus | Isolation and Characterization of Clonal Adult Human Brown Adipocytes |
-2.1 | | ZC4H2 | 'Growth Medium' vs 'none' in 'normal' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
-2.1 | | ZC4H2 | 'astrocyte overexpressing 7 genes' vs 'glioblastoma cell line' | phenotype | Transcription profiling by array of human primary astrocytes, cancer stem cells derived from astrocytes overexpressing various oncogenic and iPSC-inducing factors, glioma stem cells and gliblastomat cell line to compare their expression profiles and tumor-initiating capabilities |
1.9 | | ZC4H2 | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'normal' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
-1.9 | | ZC4H2 | '786-0; renal adenocarcinoma; P04' vs '786-0; renal adenocarcinoma; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
1.9 | | ZC4H2 | '48 hour' vs '0 hour' in 'cytomegalovirus infection' | time | Transcriptome modulation analysis of cytomegalovirus-infected immature monocyte-derived dendritic cells |
1.8 | | ZC4H2 | '6 to 8 weeks post ovulation' vs 'adult' in 'normal' | developmental stage, disease | Comparison of gene expression profiling of human lung at four developmental stages and lung adenocarcioma |
1.8 | | ZC4H2 | '3 to 5 weeks post ovulation' vs 'adult' in 'normal' | developmental stage, disease | Comparison of gene expression profiling of human lung at four developmental stages and lung adenocarcioma |
-1.8 | | ZC4H2 | '786-0; renal adenocarcinoma; P10' vs '786-0; renal adenocarcinoma; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1.7 | | ZC4H2 | 'p63 knockdown by siRNA' vs 'scrambled siRNA' in 'BxPC-3' | RNA interference, cell line | RNA-seq of human pancreatic cell lines, L3.6pl and BxPC-3, upon knockdown of p63 for 48 hours compared to siControl |
1.7 | | ZC4H2 | 'MDAMB231; cocultured with fibroblast CCD1112Sk' vs 'MDAMB231; normal' | cell line, growth condition | System-Wide Analysis Reveals a Complex Network of Tumor-Fibroblast Interactions Involved in Tumorigenicity |
-1.7 | | ZC4H2 | 'malignant mesothelioma; ERK1 knockdown' vs 'malignant mesothelioma; scrambled control' | disease, genotype | Expression profile of shERK1, shERK2, shERK5 and shControl HMESO cells |
-1.7 | | ZC4H2 | 'malignant mesothelioma; ERK5 knockdown' vs 'malignant mesothelioma; scrambled control' | disease, genotype | Expression profile of shERK1, shERK2, shERK5 and shControl HMESO cells |
-1.7 | | ZC4H2 | 'T-helper 1 polarising' at '1 day' vs 'no stimulus' | cell type, sampling time point, stimulus | Transcription profiling by array of human CD4+T-cells, Th1/Th2 polarized time-series and primary memory subsets |
1.7 | | ZC4H2 | 'EX00000246' vs 'none' in 'unstimulated' at '6 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
-1.7 | | ZC4H2 | 'tumor' vs 'normal' | clinical information | Transcription profiling by high throughput sequencing in esophageal squamous cell carcinoma cells. |
-1.6 | | ZC4H2 | 'phorbol 13-acetate 12-myristate; 100 nanomolar; interleukin-4 and interleukin-13; 2 day' vs 'none; none; 0 day' | compound, stimulus, time | Transcriptional profiling of THP1-derived human macrophages with different stimuli |
1.6 | | ZC4H2 | 'cisplatin; 100 micromolar' vs 'none' in 'TMEM45A knockdown by siRNA' | RNA interference, compound | RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin |
-1.6 | | ZC4H2 | 'T-helper 2 polarising' at '1 day' vs 'no stimulus' | cell type, sampling time point, stimulus | Transcription profiling by array of human CD4+T-cells, Th1/Th2 polarized time-series and primary memory subsets |
1.6 | | ZC4H2 | 'expressing O6-methylguanine methyltransferase' vs 'control' | phenotype | MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib |
-1.6 | | ZC4H2 | 'sepsis' vs 'normal' in 'whole blood' | cell type, disease, treatment | Next generation sequencing of human immune cell subsets across diseases |
1.6 | | ZC4H2 | 'BRD4 inhibitor JQ1' vs 'none' in '92' | cell line, compound | Transcription profiling by array of uveal melanoma cell lines with wild type and mutant G-proteins (GNAQ or GNA11) in response to treatment with BRAD4 inhibitor JQ1 |
-1.5 | | ZC4H2 | 'human intestinal organoids derived from H9 stem cells' vs 'Undifferentiated H9 Stem Cells' | cell type | Transcriptional Profiling of human pluripotent stem cells and and derived tissues |
1.5 | | ZC4H2 | 'Barrett’s esophagus; low-grade dysplasia' vs 'normal' | disease, disease staging | Whole transcriptome profiling of Esophageal adenocarcinoma and Barrett's |
1.5 | | ZC4H2 | 'SDHB siRNA' vs 'control' | rnai, RNA interference | Transcripton profiling by array of human siRNA silenced SDHB HepB3 cells |
-1.5 | | ZC4H2 | 'fibroblast; Klinefelter’s Syndrome' vs 'embryonic stem cell; control' | cell type, disease | Expression data of the iPSCs derived from foreskin fibroblast cells of normal person and KS patient |
1.5 | | ZC4H2 | 'MOLT-4; acute lymphoblastic leukemia; P04' vs 'MOLT-4; acute lymphoblastic leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1.5 | | ZC4H2 | 'SARS coronavirus Urbani ΔORF6 mutant' vs 'mock' at '54 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1.5 | | ZC4H2 | 'phorbol 13-acetate 12-myristate; 100 nanomolar; interleukin-4; 2 day' vs 'none; 3 day' in 'none; none; 0 day' | compound, stimulus, time | Transcriptional profiling of THP1-derived human macrophages with different stimuli |
1.5 | | ZC4H2 | 'DU-145; converted to docetaxel resistant cells' vs 'DU-145; none' | cell line, treatment | Expression data from docetaxel-resistant prostate cancer cell lines |
1.5 | | ZC4H2 | 'DMSO' in 'stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '6 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
-1.4 | | ZC4H2 | 'PAX2 siRNA' vs 'control' | RNA interference | Transcription profiling by high throughput sequencing of control- and PAX2-siRNA-transfected human epididymis epithelial cells |
1.4 | | ZC4H2 | 'DMSO; prostate carcinoma' at '24 hour' vs 'DMSO; normal' at '24 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
-1.4 | | ZC4H2 | 'SARS coronavirus Urbani ΔORF6 mutant' vs 'mock' at '60 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
1.4 | | ZC4H2 | 'MOLT-4; acute lymphoblastic leukemia; P01' vs 'MOLT-4; acute lymphoblastic leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1.4 | | ZC4H2 | 'Human betacoronavirus 2c EMC/2012' vs 'mock' at '24 hour' | infect, time | Transcription profiling of human bronchial epithelial cell line Calu-3 2B4 infected with Human Coronavirus EMC 2012 |
1.4 | | ZC4H2 | 'MDAMB231; cocultured with fibroblast HFF1' vs 'MDAMB231; normal' | cell line, growth condition | System-Wide Analysis Reveals a Complex Network of Tumor-Fibroblast Interactions Involved in Tumorigenicity |
-1.4 | | ZC4H2 | 'SPRY1 knockdown by siRNA' vs 'none' | RNA interference | Loss of Spry1 reduces growth of BRAFV600E-mutant cutaneous melanoma and improves response to targeted therapy |
1.4 | | ZC4H2 | '; hTERT/E6/E7; MSCV-HOXA9' vs '; hTERT/E6/E7; control' | RNA interference, cell line, phenotype | HOXA9 transcriptomic analysis in GBM cell lines (U87MG, U251 and primary GBML18) and in immortalized human astrocytes (hTERT/E6/E7) |
-1.4 | | ZC4H2 | 'non-inflammatory breast cancer' vs 'normal' | disease | Expression Analysis of Microdissected Inflammatory Breast Cancer |
-1.4 | | ZC4H2 | 'astrocyte overexpressing 4 genes' vs 'glioblastoma cell line' | phenotype | Transcription profiling by array of human primary astrocytes, cancer stem cells derived from astrocytes overexpressing various oncogenic and iPSC-inducing factors, glioma stem cells and gliblastomat cell line to compare their expression profiles and tumor-initiating capabilities |
-1.4 | | ZC4H2 | 'inflammation' vs 'normal tissue adjacent to inflammation' in 'ulcerative colitis; colon' | disease, organism part, sampling site | RNA-seq of biopsies, crypts and organoids of inflamed and non-inflamed biopsies of ulcerative colitis patients |
-1.4 | | ZC4H2 | 'non-triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
1.4 | | ZC4H2 | 'poly(I:C); 25 microgram per milliliter' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.3 | | ZC4H2 | 'SNCA overexpression' vs 'wild type genotype' | genotype | RNA-seq of human midbrain organoid models of Parkinson's Disease |
1.3 | | ZC4H2 | 'Human gammaherpesvirus 4' at '14 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1.3 | | ZC4H2 | '5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide; 0.4 millimolar' vs 'none' | compound | Transcriptome of primary acute myeloid leukemia (AML) cells treated with AICAr |
1.3 | | ZC4H2 | 'CLF1' vs 'CLS1; co-culture with CAF to generate sphere' | cell line, growth condition, passage | Cancer-Associated Fibroblasts Support Lung Cancer Stemness through Paracrine IGF-II/IGF1R/Nanog Signaling |
-1.3 | | ZC4H2 | 'phorbol 13-acetate 12-myristate; 100 nanomolar' at '3 day' vs 'none' at '0 day' in 'none' | compound, stimulus, time | Transcriptional profiling of THP1-derived human macrophages with different stimuli |
-1.3 | | ZC4H2 | 'SARS coronavirus Urbani ΔORF6 mutant' vs 'mock' at '48 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1.3 | | ZC4H2 | 'Cisplatin' vs 'None' in 'A2780; Hypoxia' | cell line, compound, growth condition | Analysis of gene expression changes in response to hypoxia and/or cisplatin in A2780 and A2780cis cells |
-1.3 | | ZC4H2 | 'paediatric' vs 'foetal' in 'epithelial cell of large intestine' | cell type, developmental stage | Transcriptional profiling by array of intestinal epithelial cells from foetal and paediatric gut |
-1.3 | | ZC4H2 | '24 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
1.2 | | ZC4H2 | '16 to 24 weeks post ovulation' vs 'adult' in 'normal' | developmental stage, disease | Comparison of gene expression profiling of human lung at four developmental stages and lung adenocarcioma |
-1.2 | | ZC4H2 | 'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; co-culture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
1.2 | | ZC4H2 | 'p-fluorosuberoylanilide hydroxamic acid (FSAHA); 10 micromolar' vs 'none; 0 micromolar' | compound | Transcription profiling by array of human breast cancer MCF-7 cells treated with 17-AAG |
1.2 | | ZC4H2 | 'MOLT-4; acute lymphoblastic leukemia; P10' vs 'MOLT-4; acute lymphoblastic leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1.2 | | ZC4H2 | 'Human betacoronavirus 2c England-Qatar/2012; 24 hour' vs 'mock; 18 hour' | infect, time | Transcription profiling of human bronchial epithelial cell line Calu-3 2B4 infected with Human Coronavirus MERS-CoV-London |
1.2 | | ZC4H2 | 'PARK2 overexpression' vs 'control' | genotype | Expression data from PARK2 overexpression in U251 cells |
-1.2 | | ZC4H2 | 'highly invasive' vs 'poorly invasive' | phenotype | Expression data from CL1-0 and CL1-5 lung cancer cell line. |
1.2 | | ZC4H2 | 'sulforaphane; prostate carcinoma' at '6 hour' vs 'sulforaphane; normal' at '6 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
-1.2 | | ZC4H2 | 'T-helper 2 polarising' at '5 days' vs 'no stimulus' | cell type, sampling time point, stimulus | Transcription profiling by array of human CD4+T-cells, Th1/Th2 polarized time-series and primary memory subsets |
1.2 | | ZC4H2 | 'cisplatin; 100 micromolar' vs 'none' in 'scrambled siRNA' | RNA interference, compound | RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin |
-1.2 | | ZC4H2 | 'DICERER5/EX5; tunicamycin' vs 'wild type; tunicamycin' | genotype, treatment | Induction of ER stress in HCT116 colon cancer cells |
-1.2 | | ZC4H2 | 'Influenza A virus (A/California/07-00001/2009(H1N1))' vs 'none' in 'poly(I:C); 25 microgram per milliliter; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.2 | | ZC4H2 | 'neoplasm' vs 'normal tissue adjacent to tumour' | sampling site | Identification of long non-coding RNA expression patterns useful for molecular-based classification of type I endometrial cancers |
1.1 | | ZC4H2 | 'lapatinib; 500 nanomolar; 7 day' vs 'dimethyl sulfoxide; 1 day' | compound, time | RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib |
1.1 | | ZC4H2 | 'Barrett’s esophagus; non-dysplastic' vs 'normal' | disease, disease staging | Whole transcriptome profiling of Esophageal adenocarcinoma and Barrett's |
1.1 | | ZC4H2 | 'siZNF217' vs 'control' | RNA interference | Transcription profiling by high throughput sequencing of ZNF217 chromatin occupancy in the breast cancer cell genome |
1.1 | | ZC4H2 | 'Nkx2-1 overexpression' vs 'wild type' | genotype | Transcription profiling by array of A549 lung carcinoma cells expressing the transcription factor Nkx2-1 |
-1.1 | | ZC4H2 | 'Cisplatin' vs 'None' in 'A2780cis; Hypoxia' | cell line, compound, growth condition | Analysis of gene expression changes in response to hypoxia and/or cisplatin in A2780 and A2780cis cells |
1.1 | | ZC4H2 | 'FiPS generated with GATA3VP16, SOX2vP16, KLF4 and cMYC' vs 'Control fibroblasts' | cell type | Gene expression from human fibroblasts |
-1.1 | | ZC4H2 | 'SR; poorly differentiated B cell origin leukemia; P10' vs 'SR; poorly differentiated B cell origin leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
1.1 | | ZC4H2 | 'Med23 siRNA knockdown' vs 'control' | genotype | Transcriptome analysis of si-Med23 and si-Elk1 A549 cells |
1.1 | | ZC4H2 | 'sulforaphane; prostate carcinoma' at '24 hour' vs 'sulforaphane; normal' at '24 hour' | compound, disease, time | Genome-wide transcriptome analysis of the dietary chemopreventive phytochemical sulforaphane on normal and prostate cancer cells. |
1.1 | | ZC4H2 | 'TEN1-ICD-GFP-His overexpression' vs 'control' | phenotype | Studying the effects of the TEN1-ICD on transcriptional regulation |
1.1 | | ZC4H2 | 'cultured skin substitute; 28 day' vs 'skin; 0 day' | organism part, time | Transcription profiling by array of human grafted engineered skin substitutes |
-1.1 | | ZC4H2 | 'SW-620; adenocarcinoma of colon; P04' vs 'SW-620; adenocarcinoma of colon; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
1.1 | | ZC4H2 | 'cultured skin substitute; 42 day' vs 'skin; 0 day' | organism part, time | Transcription profiling by array of human grafted engineered skin substitutes |
-1 | | ZC4H2 | 'injected in NSG mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
-1 | | ZC4H2 | 'injected in NSG-HLA-A2/HHD mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
-1 | | ZC4H2 | 'wild type; 4-hydroxytamoxifen; senescent cell' vs 'wild type non-senescent cell' | compound, genotype, phenotype | Analysis of the senescent transcriptome upon expression of a ZFP36L1 phosphomutant |
1 | | ZC4H2 | 'lapatinib; 500 nanomolar; 1 day' vs 'dimethyl sulfoxide; 1 day' | compound, time | RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib |
-1 | | ZC4H2 | 'tumor tissue' vs 'adjacent non-tumor tissue' | sampling site | RNA-seq of prostate cancer and adjacent normal tissues from 14 patients |
-1 | | ZC4H2 | 'Numb4 overexpression' vs 'control' in 'MDAMB231' | cell line, genotype | Expression profile of MDA-MB-231 and MCF7 cells stably transfected with GFP-Numb4, GFP-Numb5, GFP-Numb6 |
1 | | ZC4H2 | 'AsPC-1; pancreatic adenocarcinoma; P04' vs 'AsPC-1; pancreatic adenocarcinoma; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1 | | ZC4H2 | 'SARS coronavirus Urbani ΔORF6 mutant' vs 'mock' at '36 hour' | infect, time | Time course analysis of icSARS CoV Urbani or icSARS deltaORF6 infected Calu-3 2B4 bronchial epithelial cells |
-1 | | ZC4H2 | 'phorbol 13-acetate 12-myristate; 100 nanomolar; lipopolysaccharide; 1 day' vs 'none; none; 0 day' | compound, stimulus, time | Transcriptional profiling of THP1-derived human macrophages with different stimuli |
-1 | | ZC4H2 | 'apical radial glial cell' vs 'neuron' | cell type | Transcription profiling by high throughput sequencing of the developing human cortex |
-1 | | ZC4H2 | '154; 0.4 micromolar' vs 'DMSO' | compound | Development of a small molecule for treatment of castration resistant prostate cancer via androgen receptor and IL6/STAT3 pathways |
1 | | ZC4H2 | 'TGFb-induced epithelial-mesenchymal transition' vs 'normal' in 'A549' | cell line, phenotype | Transcription profiling by array of three non-small cell lung cancer cell lines upon TGFb-induced epithelial-mesenchymal transition (EMT) against untreated counterparts to study EMT's role in tumour metastasis |
-1 | | ZC4H2 | 'astrocyte overexpressing 7 genes' vs 'astrocyte' | phenotype | Transcription profiling by array of human primary astrocytes, cancer stem cells derived from astrocytes overexpressing various oncogenic and iPSC-inducing factors, glioma stem cells and gliblastomat cell line to compare their expression profiles and tumor-initiating capabilities |
-1 | | ZC4H2 | 'Staphylococcus aureus strain SK2' vs 'none' | infect | Transcription profiling of human primary bone cells exposed to Staphylococcus aureus |
1 | | ZC4H2 | 'cultured skin substitute; 14 day' vs 'skin; 0 day' | organism part, time | Transcription profiling by array of human grafted engineered skin substitutes |
-1 | | ZC4H2 | 'paediatric' vs 'foetal' in 'epithelial cell of small intestine' | cell type, developmental stage | Transcriptional profiling by array of intestinal epithelial cells from foetal and paediatric gut |
-1 | | ZC4H2 | 'stimulated with interferon gamma and lipopolysaccharide' vs 'unstimulated' in 'EX00000246' at '24 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
1 | | ZC4H2 | 'doxorubicin; 5 micomolar and T0901317; 5 micromolar' vs 'none' | compound | LXR mediated-signalling protects human hair follicles against doxorubicin-induced toxicity ex vivo |
